Deals: Page 2
-
Getty Images
News roundupIambic partners with Jazz; Merck breaks ground on $3B plant
The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.
By BioPharma Dive staff • Oct. 21, 2025 -
Courtesy of Novo Nordisk
Novo wagers up to $2.1B on Omeros’ rare disease drug
The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called complement-mediated diseases.
By Delilah Alvarado • Oct. 15, 2025 -
Getty Images
Obesity drugsKailera nets $600M more to advance Zepbound-like obesity drug
Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that just succeeded in late-stage testing in China.
By Jonathan Gardner • Oct. 14, 2025 -
Getty Images
BioCryst goes ‘all in’ on rare swelling disease with Astria deal
A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema that complements its daily pill.
By Delilah Alvarado • Oct. 14, 2025 -
Getty Images
Immune resetBristol’s $1.5B Orbital buyout extends ‘in vivo’ cell therapy deal streak
The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically modify immune cells inside the body.
By Jonathan Gardner • Oct. 10, 2025 -
Getty Images
Novo joins MASH dealmaking surge with $4.7B Akero buyout
The deal is the third acquisition since May involving a drug that could reverse liver scarring in people with metabolic dysfunction-associated steatohepatitis.
By Jonathan Gardner • Oct. 9, 2025 -
Bhagavatheeshwaran, Govind. (2016). "MRI Scan" [Image]. Retrieved from Flickr.
China competitionZenas looks to China to stock pipeline with 3 more immune drugs
A potentially $2 billion deal with InnoCare Pharma hands Zenas rights to a BTK inhibitor in late-stage testing for multiple sclerosis and two other immune medicines in earlier development.
By Kristin Jensen • Oct. 8, 2025 -
Getty Images
Obesity drugsMetsera strengthens case for Pfizer buyout with latest study data
In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing of Eli Lilly’s Zepbound.
By Jonathan Gardner • Sept. 30, 2025 -
Courtesy of Genmab A/S
Genmab to acquire closely watched cancer drug in $8B Merus buyout
The deal hands Genmab a drug that showed the potential in earlier testing to extend survival in head and neck cancer when added to Merck’s widely used immunotherapy Keytruda.
By Delilah Alvarado • Sept. 29, 2025 -
Jacob Bell/BioPharma Dive
Obesity drugsPfizer buys back into obesity drug chase with $4.9B Metsera deal
The deal ends a short run as a publicly traded company for Metsera, which is being sold for more than double its IPO price amid enthusiasm for its weight loss medicines.
By Jonathan Gardner • Sept. 22, 2025 -
Jacob Bell/BioPharma Dive
Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs
The purchase gives Biogen full access to an implantable device that could help patients avoid the repeat lumbar punctures required for drugs like Spinraza.
By Kristin Jensen • Sept. 18, 2025 -
Getty Images
Roche dives into MASH with $2.4B deal for 89bio
Roche’s CEO claimed 89bio’s drug, which is in late-stage testing, has the potential to show “best-in-disease efficacy” for many people with the condition.
By Ben Fidler • Sept. 18, 2025 -
Getty Images
CSL nabs option to acquire a startup and its blood-clotting drug
A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding.
By Kristin Jensen • Sept. 16, 2025 -
Getty Images
Novartis to gain heart drug in $1.4B deal for Tourmaline Bio
Tourmaline recently unveiled mid-stage trial data for its anti-inflammatory drug, which is ready for Novartis to advance into Phase 3 testing for heart disease.
By Delilah Alvarado • Sept. 9, 2025 -
Getty Images
China competitionBravehart, a stealthy startup, looks to China to challenge Bristol Myers heart drug
Led by the former CEO of Hi-Bio and backed by notable investors, the startup licensed from Hengrui a drug it claims is superior to Bristol Myers' Camzyos as well as other, similar medicines.
By Ben Fidler • Sept. 5, 2025 -
Getty Images
Brain drug revivalNovartis thinks Arrowhead brain drug can succeed where others couldn’t
A licensing deal worth at least $200 million will give Novartis access to a preclinical RNA medicine designed to combat diseases like Parkinson’s.
By Jacob Bell • Sept. 2, 2025 -
Getty Images
Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales
An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which is sold by Amgen.
By Jonathan Gardner • Aug. 25, 2025 -
Getty Images
AbbVie wagers more than $1B on Gilgamesh’s psychedelic drug
The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive Phase 2 results in major depression.
By Jacob Bell • Aug. 25, 2025 -
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
Startup Formation Bio acquired rights to a brain-penetrating TYK2 inhibitor, while Pfizer inked its second large licensing deal with a China-based drugmaker this year.
By Ben Fidler • Updated Dec. 9, 2025 -
Courtesy of Gilead
Emerging biotechGilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius
The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could that potentially widen access to CAR-T treatment.
By Jonathan Gardner • Aug. 21, 2025 -
Getty Images
Biotech zombiesXoma, a drug royalty specialist, buys another ‘zombie’ biotech
A deal to acquire Alkermes spinout Mural Oncology is Xoma’s fourth since June and the latest evidence of interest in buying and shutting down struggling drugmakers.
By Ben Fidler • Aug. 20, 2025 -
Getty Images
China competitionExpedition, a startup searching for drugs from China, cuts its first deal
The startup agreed to pay Fosun Pharma as much as $645 million for a drug in testing for multiple lung conditions, including bronchiectasis.
By Ben Fidler • Updated Aug. 12, 2025 -
Courtesy of CureVac AG
VaccinesBioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal
The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an acquisition of its one-time COVID-19 vaccine competitor.
By Jonathan Gardner • Aug. 8, 2025 -
Alamy
Brain drug revivalIn rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A
A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggests big pharma may finally be willing to place significant bets on psychedelics.
By Jacob Bell • July 31, 2025 -
Ann Czichos via Getty Images
VaccinesBavarian Nordic agrees to $3B take-private deal
The vaccine maker’s board intends to recommend a pending offer from investment firms Nordic Capital and Permira, which would take over the drugmaker and delist it from market.
By Delilah Alvarado • July 29, 2025
Previous
